Introduction
============

Mucus composition
-----------------

The visco-elastic mucus gel layer consists of an outer loose layer containing gut microbiota and an inner more compact layer devoid of any bacteria (Johansson et al., [@B24]). The thickness of the mucus layer ranges from 10 μm in the eye to 700 μm in the intestine (Linden et al., [@B29]). Mucin glycoproteins are the main components of mucus while others include; cathelicidins, defensins, lysozyme, protegrins, collectins, antibodies, nitric oxide, and histatins. Collectively these constituents of mucus form a physical barrier, participate in bacterial clearance, and display antimicrobial activity (Linden et al., [@B29]; McGuckin et al., [@B33]). Other protective bioactive molecules in mucus include trefoil factors involved in the repair and restitution of the epithelial mucosa (Taupin and Podolsky, [@B54]), and resistin-like molecule β (Relmβ) which contribute to the barrier properties of mucus by enhancing mucin gene expression and preventing bacteria from breaching the mucus layer (Hogan et al., [@B18]; Krimi et al., [@B27]). In general, mucus protects underlying epithelial cells from chemical, microbial, enzymatic, and mechanical damage.

The main component of mucus, mucin glycoproteins, are heavily *o*-glycosylated in large peptide domains harboring repeats of the amino acids serine and threonine. These areas are known as variable number tandem repeat (VNTR) regions and vary in length both between individuals and different mucin types, leading to VNTR polymorphisms. Carbohydrates constitute approximately 70% of the mass of mucin glycoproteins, conferring mucins with water holding capacity, rigidity, protease resistance, and a high charge density (Klein et al., [@B25]; Moncada et al., [@B35]). Up to 16 human mucins have been described, falling into three subfamilies: secreted mucins (MUC7), cell surface mucins (MUC1, MUC4, MUC3A/B, MUC12, MUC13, MUC15, MUC16, MUC 17, MUC20), and gel-forming mucins (MUC2, MUC5AC, MUC5B, MUC6, and MUC19). A cluster of four genes on chromosome 11 encode gel-forming mucins, which are the main mucin subfamily in mucus and confer its visco-elastic properties. Cysteine residues at the N- and C-termini of gel-forming mucins form intermolecular and intramolecular disulfide bonds, leading to homo-oligomerization of mucins in regions known as von Willebrand factor-like or D domains (Moncada et al., [@B35]; Linden et al., [@B29]). In the gastrointestinal tract, mucin types are differentially expressed. Mucin sub-types in the colon include MUC2, MUC1, MUC3A/B, MUC4, MUC12, MUC13, MUC15, MUC17, and MUC20. The stomach contains MUC5AC, MUC6, MUC1, MUC4, MUC12, MUC13, and MUC17, while small intestinal mucins include MUC2, MUC3A/B, MUC12, MUC13, MUC15, and MUC17 (Moran et al., [@B38]).

Mucus and enteric bacterial pathogens
-------------------------------------

Enteric pathogens have to colonize and circumvent the mucus layer prior to causing disease. To establish infection, these bacteria have to bypass both physical and immunological barriers in the gastrointestinal tract. The visco-elastic mucus gel layer protects underlying epithelial cells by trapping pathogens in the loose mucus and clearing them both during gut movements and mucus turnover. In addition, mucin glycoproteins bind and retard bacteria in mucus, preventing them from accessing epithelial cells. Furthermore, antimicrobial peptides present in mucus and gut microflora are directly antagonistic to pathogens. Intestinal microbiota also competitively exclude gut pathogens by occupying mucin receptors, hence preventing pathogen access to the mucosa (reviewed in Linden et al., [@B29]).

Enteric pathogens typically breach the mucus layer by employing mucus degradative enzymes. Mucinases, sialidases, *N*-acetyl neuraminate lyases, glycosulfatases, and sialate *o*-acetylesterases are some of the mucinolytic enzymes employed by gut pathogens (Corfield et al., [@B7], [@B8]; Haider et al., [@B14]; Homer et al., [@B19]). For example *Vibrio cholerae* expresses HapA which has both mucinolytic and cytotoxic activity (Silva et al., [@B46]). In addition, chemotaxis and flagellar motility facilitate colonization and penetration of the mucus barrier by enteric pathogens (discussed below for *Campylobacter jejuni*).

In response to the presence of gut microbes, mucin synthesis and glycosylation are regulated. Adherence by probiotic bacteria and products from some bacteria increase the synthesis of mucins from epithelial cells (Smirnova et al., [@B48]). For example, colonic Muc1 expression is upregulated in both mouse and human intestinal bacterial infections (Linden et al., [@B28]). Furthermore, mucin glycosylation changes have been documented following *Helicobacter pylori* infection (reviewed in Moran et al., [@B38]) and *H. pylori* lipopolysaccharide (LPS) inhibits mucin synthesis in gastric epithelial cells (Slomiany and Slomiany, [@B47]). *H. pylori* and the stomach gel-forming mucin MUC5AC have been shown to colocalize, and these bacteria bind the dimeric form of the human recombinant trefoil factor 1 (TFF1; Van den Brink et al., [@B56]; Clyne et al., [@B6]). Recently, it has been shown that *H. pylori* binds TFF1 by means of its rough form LPS in a pH dependent manner (Reeves et al., [@B43]). The mechanism of bacterial LPS binding to TFF1 is not known. However, TFF1 harbors a hydrophobic patch of solvent-exposed residues on its surface which may act as a possible carbohydrate binding domain (Reeves et al., [@B43]). In addition, a pH of between 5 and 6 was found to be optimal for the interaction between TFF1 and *H. pylori*. This pH range is typical of that found in the mucosal niche occupied by *H. pylori* *in vivo* supporting the possibility that *H. pylori* binding to TFF1 may promote bacterial colonization in the stomach (Schreiber et al., [@B45]; Reeves et al., [@B43]).

From the above it is clear that while on the one hand components of mucus influence bacterial colonization and virulence properties, on the other, the presence of bacteria has a marked effect on mucin expression. Therefore, while the mucus layer and its constituents form part of the innate defense against pathogens, mucosal organisms have evolved remarkable strategies to circumvent (or even subvert for their own advantage) this barrier.

The Interaction of *C. jejuni* with Mucus and Mucins
====================================================

Mucus and mucins as a barrier in *C. jejuni* infection
------------------------------------------------------

Much of our understanding of how intestinal mucins protect the mucosa from infection with *C. jejuni* has evolved only recently, led by groundbreaking work from McGuckin and colleagues at the University of Queensland (McAuley et al., [@B32]; Linden et al., [@B28],[@B29]; Dawson et al., [@B9]). The cell surface mucin, Muc1, was found to be upregulated following infection with both the natural mouse pathogen *Citrobacter rodentium* and with *C. jejuni* (McAuley et al., [@B32]; Linden et al., [@B28]). Muc1 negative mice were shown to have a marked increase in translocation of *C. jejuni* to systemic organs. In addition Muc1 is upregulated in human colonic biopsies following naturally occurring *C. jejuni* infection (Linden et al., [@B28]). A not dissimilar role for mucin sulfation in the protection of mice from *C. jejuni* systemic infection (a marker of intestinal barrier function) subsequently was demonstrated using a mouse Nas1 knockout model (Dawson et al., [@B9]). Interestingly, while Muc1 also has a role in protecting mice from *H. pylori* infection, it does not help protect mice from the pathologic effects of *H. felis* infection (Every et al., [@B11]). From these experiments, it is obvious that the mucus barrier has evolved a complex array of protective mechanisms against infection and these appear not to be simply generic antibacterial barriers. Nonetheless, it will be important to attempt to document the role of these mucus characteristics in *Campylobacter* models that approximate more closely those of human infection, a problem that continues to bedevil the wider field of *Campylobacter* pathogenesis.

Adaptations of *C. jejuni* to life in the mucus layer
-----------------------------------------------------

Ultimately, *C. jejuni* is very successful in overcoming the intricate barrier structures posed by mucus and mucins in order to establish enteric infection, at least in the human intestinal tract. While the exact details of how *C. jejuni* establishes infection remain elusive, the complex interplay between bacterium and host mucosal surface has been the subject of intensive research in recent years and an understanding is beginning to emerge of the role of mucus in that relationship.

### Motility/chemotaxis

Flagellar motility and chemotaxis toward components of mucus are thought to be crucial in the life cycle of *C. jejuni*, both as a commensal and as a pathogen. Virulence in the ferret model, host colonization, adhesion, and invasion all require flagellar motility (Young et al., [@B58]). Chemotaxis receptors together with other elements of the *C. jejuni* chemotaxis and motility machinery are known to be required for colonization in a chick model of infection (Hendrixson and DiRita, [@B16]). Likewise, flagellar genes and regulators of flagellar biosynthesis such as FlgR, σ^28^, and σ^54^ are all required for chick colonization (Hendrixson, [@B15]). Chemoattractants for *C. jejuni* include amino acids such as [l]{.smallcaps}-glutamate, [l]{.smallcaps}-serine, [l]{.smallcaps}-cysteine, [l]{.smallcaps}-aspartate, and the sugar fucose (Hugdahl et al., [@B22]; Szymanski et al., [@B53]).

In solutions of increased viscosity comparable to mucus, *C. jejuni* is highly motile, demonstrating peaks of motility with longer path lengths (Ferrero and Lee, [@B12]; Szymanski et al., [@B52]). The corkscrew-like shape of these bacteria and the relatively short O-side chains of its lipooligosaccharide (LOS) are purported to prevent non-specific binding of *C. jejuni* to mucin glycoproteins (McSweegan and Walker, [@B34]). This suggests an adaptation of these bacteria to the environment of mucus, thus conferring *C. jejuni* with an ecological advantage while in mucus (Ferrero and Lee, [@B12]). Increased motility of *C. jejuni* in highly viscous solutions correlates with increased virulence *in vitro*. Pre-incubation of *C. jejuni* in media of increased viscosity increases bacterial binding and internalization into Caco-2 cells (Szymanski et al., [@B52]).

### Reproduction in mucus

*Campylobacter jejuni* has been shown to reproduce in chicken mucus (Van Deun et al., [@B57]). Van Deun et al. showed that *C. jejuni* multiplies in PBS supplemented with mucus but not in PBS alone or chicken cecal contents. In agreement with these findings, we have recently demonstrated *C. jejuni* replication in growth medium supplemented with mucus derived from a mucus-adherent subclone of methotrexate treated HT29 cells, HT29MTXE12 (E12; Alemka et al., [@B1]). We also showed that *C. jejuni* reproduced following colonization of E12 cells (with mucus), compared with HT29 cells that lacked a mucus layer. Taken together, these studies indicate that *C. jejuni* grows and thrives in the mucus milieu, an adaptation that likely helps to ensure its persistence in the host.

### Adhesion/invasion and pathogenicity

Conventional tissue culture has contributed greatly to our understanding of how enteric pathogens such as *C. jejuni* elaborate disease. For instance, infection studies with intestinal epithelial cells led to the identification of *C. jejuni* adhesins such as CadF. CadF, also required for chick colonization (Ziprin et al., [@B59]), binds fibronectin located at the basolateral aspects of cells, and facilitates bacterial internalization (Monteville et al., [@B37]; Krause-Gruszczynska et al., [@B26]). Likewise, JlpA, a lipoprotein on the surface of *C. jejuni*, interacts with heat shock protein 90α leading to the activation of p38 mitogen activated protein kinases (MAPK) and NF-κB, thereby eliciting pro-inflammatory responses in Hep-2 cells (Jin et al., [@B23]). In addition, both microtubules (Hu and Kopecko, [@B20]) and the actin cytoskeleton (Monteville et al., [@B37]; Krause-Gruszczynska et al., [@B26]) are involved in *C. jejuni* invasion. Furthermore, these bacteria translocate cultured intestinal epithelial cells by migrating through both the paracellular (Monteville and Konkel, [@B36]) and transcellular routes (Bras and Ketley, [@B4]; Hu et al., [@B21]).

Despite the utility of conventional cell lines, the absence of an adherent mucus layer on these models is a significant weakness. In order to overcome this, we have attempted to better understand the role of mucus in infection by characterizing the interaction of *C. jejuni* with E12 cells (Behrens et al., [@B3]; Alemka et al., [@B1]). E12 cells were first validated as an appropriate *in vitro* model of *Campylobacter*--host interactions by demonstrating mucus colonization (Figure [1](#F1){ref-type="fig"}), adhesion, invasion, and translocation to the basolateral aspects of cells. Compared with parental HT29 cells that lack a mucus layer, there was enhanced bacterial binding and internalization into E12 cells (Alemka et al., [@B1]). Combined with previous studies (de Melo and Pechere, [@B10]; Szymanski et al., [@B52]; Byrne et al., [@B5]) these findings indicate that *C. jejuni* not only has evolved mechanisms to breach the protective mucus barrier layer, but also appears to have subverted the mucus to enhance pathogenicity. In support of this concept, the presence of MUC2 (the main intestinal gel-forming mucin) has been shown to upregulate a number of *C. jejuni* virulence genes, including those involved in motility (*flaA*), adhesion (*jlpA*), invasion (*ciaB*), and toxin formation (*cdt*; Tu et al., [@B55]).

![**Fluorescence microscopy image of *C. jejuni* colonization of E12 mucus**. E12 cells were grown for 14 days in transwell inserts and infected with *C. jejuni*. The filter was excised and wrapped between two pieces of frozen liver and sections probed with DAPI **(A)** to reveal cell nuclei and **(B)** anti-*Campylobacter* antibodies. Mag: ×400.](fcimb-02-00015-g001){#F1}

Which component or characteristic of mucus and mucin that modulates *C. jejuni* pathogenicity is not known. However, recent studies have suggested some intriguing possibilities. It has long been known that *C. jejuni* does not metabolize glucose due to the absence of the enzyme phosphofructokinase in its genome (Parkhill et al., [@B41]; Guccione et al., [@B13]) and, because of the absence of genes involved in sugar metabolism (Parkhill et al., [@B41]; Muraoka and Zhang, [@B39]), it has generally been assumed that this organism is unable to use any form of carbohydrate as a substrate. Rather these bacteria use amino acids such as glutamate, asparagine, proline, serine, and aspartate as a source of carbon (Guccione et al., [@B13]; Hofreuter et al., [@B17]).

However, *C. jejuni* was recently shown to metabolize fucose (Muraoka and Zhang, [@B39]; Stahl et al., [@B49]). In these studies, growth of *C. jejuni* was enhanced in media supplemented with fucose. Several strains of *C. jejuni* now have been shown to possess a genomic island that is linked with the ability to take up and utilize fucose as a source of carbon (Stahl et al., [@B49]). In light of the fact that *Campylobacter* displays chemotaxis to mucin (which harbors fucosylated glycans), binds to mucin (Sylvester et al., [@B51]), and the finding that these bacteria reproduce in both human and chicken mucus (Van Deun et al., [@B57]; Alemka et al., [@B1]), it is tempting to speculate that *C. jejuni* acquires and utilizes constituents of mucus to sustain its commensal and pathogenic modes of existence, and that differences in the composition of mucus across species may contribute to *C. jejuni* pathogenicity in humans as opposed to commensalism in other animals (discussed below). Furthermore, the importance of the interaction of *C. jejuni* with fucosylated structures possibly could be exploited as a novel antimicrobial therapy in *C. jejuni* infections (Ruiz-Palacios et al., [@B44]).

### Influence of gut microbiota in the mucus layer

In the gut, microbiota are known to colonize the outer loose mucus layer (Johansson et al., [@B24]). It is thought that microbiota protect the gut from invading enteric pathogens by competing for nutrients and mucosal binding sites with pathogens, by modulating the mucosal immune response and also through direct antagonism (Neish, [@B40]). Many commensal derived bacteria have been proposed as potential anti infective probiotics. On this basis, we investigated the effect of probiotic colonization of the mucus of E12 cells on *C. jejuni* pathogenicity (Alemka et al., [@B1]). Individual probiotic strains (*Lactobacillus rhamnosus*, *L. salivarius*, *Bifidobacterium longum*), or cocktails of these probiotics, reduced *C. jejuni* colonization, invasion, and translocation of mucus-adherent E12 cells in a strain dependent manner. Pre-colonization of E12 mucus with probiotics was required to attenuate *C. jejuni* virulence, suggesting that probiotics have a potential as prophylactic agents against *C. jejuni* infections. The potential use of probiotics to reduce *Campylobacter* numbers in chickens and thereby prevent zoonotic transmission may be a particularly attractive strategy to reduce the burden of illness in humans.

Chicken Mucus and *Campylobacter* Commensalism
==============================================

The consumption of contaminated poultry is the principal mode of transmission of *C. jejuni* to humans. Up to 100% of point-of-sale chicken has been shown to be contaminated with *C. jejuni* (Madden et al., [@B31]; Pearson et al., [@B42]). Despite heavy colonization (up to 10^10^ colony forming units per gram of infected intestine) in chickens, *C. jejuni* does not cause disease. These bacteria avidly colonize the mucus layer of deep cecal crypts, but do not adhere to or invade chicken intestinal epithelial cells (reviewed in Young et al., [@B58]).

Why *C. jejuni* is pathogenic in the human population but establishes a commensal mode of existence in chickens is uncertain. An obvious difference between humans and chickens is body temperature. The human body temperature is 37°C while it ranges from 41 to 45°C in chickens. Campylobacters are therefore adapted to higher temperatures in chickens but the effect of temperature on the pathogenicity of *C. jejuni* is not yet fully understood. The two-component system RacRS has been implicated as possibly influencing the adaptation of *C. jejuni* to temperature. Mutants in this regulatory pathway show defects in viability at 42°C, suggesting that it may contribute to the survival and growth of *C. jejuni* at higher temperatures (MacKichan et al., [@B30]). In addition, differences in *Campylobacter* gene expression have been reported following growth at 37°C compared with 42°C. In one such study (Stintzi, [@B50]), at 42°C, there was an increase in the expression of chemotaxis and motility genes and an overall 20% general difference in gene expression compared with 37°C. Therefore, body temperature may influence the commensal versus pathogenic lifestyles of *C. jejuni*. However, temperature alone is unlikely to account for the difference in clinical manifestation across species.

We originally hypothesized that species-specific tissue tropism might contribute to the differences in clinical outcome of *Campylobacter* infection in humans and chickens. However, we (Byrne et al., [@B5]) and others (Van Deun et al., [@B57]) subsequently showed that *C. jejuni* both adheres to and invades chicken primary intestinal cells. These data indicate that *Campylobacter* commensalism in chickens as opposed to pathogenicity in humans is not due to lack of the relevant adhesin--receptor interactions that mediate invasiveness in the chicken intestinal epithelium. In light of these findings we investigated the possibility that intestinal mucus contributes to the inhibitory effect of the chicken intestinal milieu on *C. jejuni* virulence. We demonstrated that crude chicken intestinal mucus, markedly attenuates *C. jejuni* binding and internalization (Byrne et al., [@B5]). Consistent with these findings, mucus colonization of the human mucus-adherent E12 cell line increased *C. jejuni* adhesion and invasion of E12 cells (Alemka et al., [@B1]). Subsequently we demonstrated that purified chicken intestinal mucins, when pre-incubated with *C. jejuni*, preferentially attenuate bacterial internalization into HCT-8 cells (Figure [2](#F2){ref-type="fig"}). The effect depends on the region of the chicken gut from where mucins are isolated (Alemka et al., [@B2]). In the same study, attenuation of bacterial invasion by chicken mucins appeared to have been mediated by mucin glycans, since sodium metaperiodate treatment of chicken mucins abolished the attenuating effect of purified mucins on bacterial internalization. Intriguingly, removal of terminal fucose or sialic acid residues failed to inhibit the effect of chicken mucin on *C. jejuni* invasion. However, as chicken mucin glycoproteins are heavily sulfated compared with human mucins (unpublished observations), sulfation may have limited the activity of the fucosidase and sialidase enzymes used in our study (Alemka et al., [@B2]). Conversely, it is possible that sulfation of mucin oligosaccharides may in itself influence *C. jejuni* mucus colonization and pathogenicity across species. Taken together, these data indicate that mucus and mucins modulate *C. jejuni* virulence properties and may contribute to the differential clinical manifestations exhibited by *C. jejuni* in different hosts (Figure [3](#F3){ref-type="fig"}).

![**Purified chicken intestinal mucins attenuate *C. jejuni* invasion depending on the region of the chicken gut from which mucins were isolated (Alemka et al., [@B2], reproduced with permission)**. *C. jejuni* was pre-incubated with mucins prior to infecting HCT-8 cells. Cae, mucin from the cecum; SI, small intestinal mucins; LI, large intestinal mucins. \*Denotes significant difference compared to control. Cae *p* \< 0.05, *p* \< 0.005 for SI and LI. Hundred percentage mucin represents 1 mg/ml.](fcimb-02-00015-g002){#F2}

![**Hypothetical model of how mucus and mucins modulate the pathogenicity of *C. jejuni* in a species-specific manner:** in mucus *C. jejuni* displays chemotaxis and flagellar motility toward components of mucin. The characteristic spiral shape and the ability of *C. jejuni* to replicate in mucus suggests an adaptation of these bacteria to the mucus milieu. Interaction with human mucin enhances bacterial binding and internalization into underlying epithelial cells. In chickens, mucin glycoproteins prevent *C. jejuni* association with intestinal epithelial cells, possibly by interfering with their transit through the inner mucus layer and/or onto the appropriate host cell receptors.](fcimb-02-00015-g003){#F3}

Conclusion and Future Perspectives
==================================

The visco-elastic mucus gel layer is part of the innate defense mechanism against infecting bacteria. Mucus colonization by enteric pathogens influences the outcome of infection with these bacteria employing a variety of mechanisms to circumvent the mucus layer and gain access to underlying epithelial cells. *C. jejuni* is attracted to and metabolizes components of mucus. These bacteria are highly motile with a characteristic spiral shape and corkscrew-like motility that suggests an adaptation to the environment of mucus. Recent studies indicate that mucus and mucins influence *C. jejuni* in a species-specific manner with chicken mucins attenuating *C. jejuni* pathogenicity. Therefore, differences in the composition of mucus and mucins across species appear to contribute to *C. jejuni* disease causing lifestyle in the human population, as opposed to commensalism in chickens. Increased knowledge and understanding of the interaction of *Campylobacter* with mucus and mucins has the potential to lead to the development of intervention strategies that take advantage of the propensity of these bacteria to inhabit the intriguing supramucosal niche that is the mucus layer.
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